Degludec Advisory Committee Is Another De Facto Delay For Novo
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.